Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Australian Clinical Labs Ltd ( (AU:ACL) ) has issued an update.
Australian Clinical Labs Limited (ACL) has reached a resolution with the Australian Information Commissioner regarding a civil penalty proceeding related to a cyberattack on its Medlab Pathology business. The Federal Court of Australia has approved an agreement requiring ACL to pay $5.8 million in civil penalties and contribute $400,000 towards legal costs, concluding the proceedings and potentially impacting ACL’s financial standing and stakeholder relations.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$3.50 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
ACL is a leading Australian private provider of pathology services, operating NATA accredited laboratories that perform a diverse range of pathology tests for doctors, specialists, patients, hospitals, and corporate clients. It is one of the largest private hospital pathology businesses in Australia, focusing on combining talented people, medical and scientific leadership, and innovative technologies to improve patient outcomes.
Average Trading Volume: 958,724
Technical Sentiment Signal: Sell
Current Market Cap: A$489.5M
See more insights into ACL stock on TipRanks’ Stock Analysis page.